Akebia and Otsuka partner for vadadustat with a deal worth over US$1 B

By Jawala Prasad

Pharma Deals Review: Vol 2017 Issue 1 (Table of Contents)

Published: 13 Jan-2017

DOI: 10.3833/pdr.v2017.i1.2217     ISSN: 1756-7874

Section: Licensing



Akebia Therapeutics has entered into a collaboration and licence agreement with Otsuka to develop and commercialise vadadustat in the US in a deal worth over US$1 B...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details